<DOC>
	<DOCNO>NCT02345863</DOCNO>
	<brief_summary>A prospective , open-label , multicenter Phase-II trial evaluate efficacy safety sequential regimen Bendamustine follow GA101 Ibrutinib follow Ibrutinib GA101 maintenance CLL patient .</brief_summary>
	<brief_title>Sequential Regimen Bendamustin B Followed GA101 Ibrutinib I CLL Patients</brief_title>
	<detailed_description>In CLL2-BIG trial allcomer CLL population indication treatment include . Patient receive 2 cycle debulking treatment bendamustin unless contraindication exist debulking indicate . Afterwards 6 cycle induction therapy GA101 ibrutinib apply , duration 28 day . Primary endpoint overall Response rate assess final restaging . Patients benefit BIG treatment enter maintenance phase trial . Maintenance treatment continue unacceptable toxicity occur three month negativity minimal residual disease [ MRD ] achieve peripheral blood patient ( clinical ) complete response ( CR ) ( clinical ) incomplete complete response [ CRi ] ( confirm 2 consecutive testing MRD within 3 month ) , progression CLL , start subsequent therapy 8 cycle maintenance ( cycle duration 84 calendar day = 3 month ) , whichever occur first .</detailed_description>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1. documented CLL require treatment ( irrespective first relapse treatment ) accord criterion international Workshop CLL [ iwCLL ] In case previously treat patient , must recover acute toxicity treatment regimen must stop within follow time period start study treatment CLL2BIG trial : chemotherapy within ≥ 28 day antibody treatment within ≥ 14 day kinase inhibitor , Bcelllymphoma 2 [ BCL2 ] antagonists immunomodulatory agent within ≥ 3 day corticosteroid may apply start BIGregimen , reduce equivalent ≤ 20mg prednisolon treatment 2 . Creatinine clearance ≥ 30 ml/min 3 . Adequate hematologic function 4 . Adequate liver function 5 . Negative serological test hepatitis B , hepatitisC RNA negative HIV test within 6 week prior registration 6 . Age least 18 year 7 . Eastern Cooperative Oncology Group [ ECOG ] status 0 2 ; ECOG 3 permit related CLL 8 . Life expectancy ≥ 6 month 9 . Ability willingness provide write informed consent adhere study visit schedule protocol requirement 1 . Transformation CLL 2 . Known central nervous system ( CNS ) involvement 3 . Patients history confirm progressive multifocal leukoencephalopathy [ PML ] 4 . Malignancies CLL currently require systemic therapy 5 . Uncontrolled infection require systemic treatment 6 . Use investigational agent would interfere study drug within 28 day prior registration 7 . Any comorbidity organ system impairment rat cumulative illness rating scale [ CIRS ] score 4 , exclude eyes/ears/nose/throat/larynx organ system lifethreatening illness , medical condition organ system dysfunction investigator´s opinion could comprise patient safety interfere absorption metabolism study drug ( e.g , inability swallow tablet impaired resorption gastrointestinal tract ) 8 . Known hypersensitivity GA101 , ibrutinib excipients 9 . Requirement treatment strong cytochrome P450 3A4 [ CYP3A4 ] inhibitors/inducers anticoagulant warfarin phenprocoumon ( marcumar ) 10 . History stroke intracranial hemorrhage within 6 month prior registration 11 . Pregnant woman nurse mother 12 . Fertile men woman childbearing potential unless : surgically sterile ≥ 2 year onset menopause willing use two method reliable contraception include one highly effective ( Pearl Index &lt; 1 ) one additional effective ( barrier ) method study treatment 18 month end study treatment . 13 . Vaccination live vaccine minimum 28 day prior registration 14 . Legal incapacity 15 . Prisoners subject institutionalized regulatory court order 16 . Persons dependence sponsor investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>CLL</keyword>
</DOC>